BridgeMD
Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial
EU CTIS ID: 2026-525838-32-00
What this study is testing
To evaluate the effect of the intervention compared with control on self-rated breathlessness intensity after 60 minutes.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Signed informed consent
- Aged 18 years or older
- Serious, chronic, life-limiting disease
- Short expected survival, defined as an no-answer to the ‘surprise question’: ‘Would you be surprised if the patient died within the next year?)[1], as judged by the trial staff
- Able to self-report symptoms
- Self-rated breathlessness at least 3/10 on ESAS-r breathlessness scale at rest
You likely can't join if
- Acute worsening of breathlessness that may be better relieved by disease-specific treatment
- Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of participation in the trial as judged by the Investigator.
- Contraindication for the intervention as judged by the Investigator, including allergy towards morphine, current or planned pregnancy.
- Treatment with methadone in any dose.
- Daily opioid dose (excluding the trial treatment) of > (more than) 160mg morphine equivalents, corresponding to more than 50 mikrogr fentanyl, 80 mg oxycodone per os, 60 mg oxycodone sc, or 16 mg hydromorphone sc during the last 24 hours.
- Received the randomized treatment as part of the trial within the previous 6 hours
See the full eligibility criteria
- Signed informed consent
- Aged 18 years or older
- Serious, chronic, life-limiting disease
- Short expected survival, defined as an no-answer to the ‘surprise question’: ‘Would you be surprised if the patient died within the next year?)[1], as judged by the trial staff
- Able to self-report symptoms
- Self-rated breathlessness at least 3/10 on ESAS-r breathlessness scale at rest
- Acute worsening of breathlessness that may be better relieved by disease-specific treatment
- Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of participation in the trial as judged by the Investigator.
- Contraindication for the intervention as judged by the Investigator, including allergy towards morphine, current or planned pregnancy.
- Treatment with methadone in any dose.
- Daily opioid dose (excluding the trial treatment) of > (more than) 160mg morphine equivalents, corresponding to more than 50 mikrogr fentanyl, 80 mg oxycodone per os, 60 mg oxycodone sc, or 16 mg hydromorphone sc during the last 24 hours.
- Received the randomized treatment as part of the trial within the previous 6 hours
- Received the randomized treatment in the trial 8 times already
- Participation or recent participation in a clinical trial with another investigational medicinal product within 30 days
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.